|1.||Williams, Gregory: 2 articles (01/2012 - 07/2011)|
|2.||Critchley, Ian: 1 article (01/2012)|
|3.||Vanscoy, Brian: 1 article (01/2012)|
|4.||Jones, Ronald N: 1 article (01/2012)|
|5.||Louie, Arnold: 1 article (01/2012)|
|6.||Kulawy, Robert: 1 article (01/2012)|
|7.||Liu, Weiguo: 1 article (01/2012)|
|8.||Thye, Dirk: 1 article (01/2012)|
|9.||Brown, David: 1 article (01/2012)|
|10.||Castanheira, Mariana: 1 article (01/2012)|
01/01/2011 - "Despite resistance to CAZ and possessing a complex β-lactamase background, NXL104 combined with CAZ proved to be very effective in murine models of infection due to contemporary highly resistant KPC-producing K. "
07/01/2011 - "The purpose of this study was to evaluate the efficacy of a human-simulated regimen of ceftaroline plus NXL104 against Enterobacteriaceae in a murine thigh infection model. "
01/01/2012 - "In this evaluation, we examined organisms carrying defined β-lactamases and identified doses and schedules of NXL104 in combination with the new cephalosporin ceftaroline, which would maintain good bacterial cell kill and suppress resistance emergence for a clinically relevant period of 10 days in our hollow-fiber infection model. "
05/01/2011 - "These results suggest that NXL104 may be useful in combination with β-lactams for the treatment of infections caused by ESBL- and AmpC-producing Enterobacteriaceae."
01/01/2011 - "Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae."